Study guide
3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies
AACN Cardiac Medicine Certification CMC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview and the CMC Test Plan
1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them
2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease
2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy
3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease
3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup
4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions
4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation
5 Chapter 5: Vascular Conditions and Vascular Interventions
5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications
6 Chapter 6: Shock States and Mechanical Circulatory Support
6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD
7 Chapter 7: Cardiac Procedures and Structural Heart Interventions
7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications
8 Chapter 8: Cardiovascular Pharmacology
8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure
9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary
9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients
10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral
10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients
11 Chapter 11: Monitoring and Diagnostics
11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography
12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions
12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease
3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies
Key Takeaways Explain This Topic AI
Dilated Cardiomyopathy (DCM) is characterized by four-chamber dilation, impaired systolic contractility (HFrEF), and heightened risk of mural thrombus and lethal ventricular arrhythmias.
Hypertrophic Cardiomyopathy (HCM/HOCM) involves dynamic left ventricular outflow tract (LVOT) obstruction, Systolic Anterior Motion (SAM) of the mitral valve, and sudden cardiac death risk driven by sarcomeric gene mutations.
Maneuvers that decrease LV volume (Valsalva, standing, nitrates) worsen LVOT obstruction and intensify the HOCM murmur, whereas maneuvers increasing preload/afterload (squatting, handgrip, fluid boluses) decrease obstruction.
Restrictive Cardiomyopathy (RCM) presents with marked diastolic dysfunction, rigid ventricular walls, severe biatrial enlargement, and classic low-voltage ECG complexes despite thickened myocardium on echocardiography (characteristic of Amyloidosis).
Takotsubo Cardiomyopathy features transient apical ballooning mimicking STEMI triggered by catecholamine surges, requiring supportive care with full LVEF recovery typically within 1 to 4 weeks.
Last updated: August 2026
3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies
Cardiomyopathies comprise a heterogeneous group of myocardial diseases associated with mechanical and/or electrical dysfunction. They are categorized based on structural and functional characteristics into three major morphological types— Dilated , Hypertrophic , and Restrictive —alongside specific stress-induced syndromes such as Takotsubo Cardiomyopathy . Mastery of these disorders is essential for the advanced cardiac nurse managing complex heart failure, hemodynamic collapse, and sudden cardiac death prevention.
Dilated Cardiomyopathy (DCM)
Dilated Cardiomyopathy is characterized by left ventricular (or biventricular) dilation and severe systolic dysfunction (LVEF < 40%) in the absence of abnormal loading conditions (like severe hypertension or valvular stenosis) or ischemic artery disease adequate to cause the global impairment.
Etiologies
Genetic / Familial: Account for 30%–50% of non-ischemic DCM cases, most commonly autosomal dominant mutations in the TTN gene (encoding the giant sarcomeric protein titin).
Toxic: Chronic alcohol abuse (alcoholic cardiomyopathy), cocaine, amphetamines, and chemotherapeutic agents (anthracyclines like doxorubicin, monoclonal antibodies like trastuzumab).
Infectious / Inflammatory: Post-viral myocarditis (Coxsackie B, Parvovirus B19, Human Herpesvirus 6, SARS-CoV-2, Chagas disease).
Peripartum Cardiomyopathy (PPCM): Development of HF in the last month of pregnancy or within 5 months post-delivery, driven by anti-angiogenic prolactin cleavage fragments.
Pathophysiology & Clinical Presentation
Impaired cardiomyocyte contractility causes an increase in end-systolic volume. Over time, progressive eccentric hypertrophy leads to chamber dilation, apical thinning, and secondary functional mitral regurgitation due to annular dilation. Patients present with classic HFrEF symptoms: progressive exertional dyspnea, orthopnea, fatigue, elevated JVP, and S3 gallop.
Diagnostic Findings & Nursing Priorities
Echocardiography: Demonstrates diffuse LV hypokinesis, enlarged LV end-diastolic diameter (> 58 mm), and reduced LVEF.
ECG: Poor R-wave progression across precordial leads, left bundle branch block (LBBB), and ventricular ectopy.
Complications & Management:
Mural Thrombus: Stasis of blood in dilated, poorly contracting chambers predisposes to apical thrombus formation. Systemic anticoagulation is indicated if thrombus is visualized or if concurrent atrial fibrillation occurs.
Arrhythmia Prevention: Primary prevention Implantable Cardioverter-Defibrillator (ICD) placement is indicated for patients with LVEF ≤ 35% despite ≥3 months of optimal GDMT.
Cardiac Resynchronization Therapy (CRT-D): Indicated for patients in sinus rhythm with LVEF ≤ 35%, LBBB morphology, and QRS duration ≥ 150 ms to correct electromechanical dyssynchrony.
Loading diagram... Pathophysiology and Dynamic Modulation of HOCM Obstruction
Hypertrophic Cardiomyopathy (HCM / HOCM)
Hypertrophic Cardiomyopathy is a genetic cardiac disease defined by unexplained left ventricular hypertrophy (wall thickness ≥ 15 mm) occurring in the absence of hypertensive or valvular heart disease. It is the leading cause of sudden cardiac death in young competitive athletes.
Pathophysiology & Dynamic LVOT Obstruction
Approximately two-thirds of HCM patients exhibit dynamic Left Ventricular Outflow Tract (LVOT) obstruction at rest or with provocation (Hypertrophic Obstructive Cardiomyopathy - HOCM).
Asymmetric Septal Hypertrophy (ASH): Hypertrophy disproportionately affects the anterior interventricular septum relative to the posterior LV wall (septal-to-posterior wall ratio > 1.3:1).
Systolic Anterior Motion (SAM): Rapid systolic ejection through the narrowed LVOT creates a suction drag (Venturi effect), pulling the anterior leaflet of the mitral valve forward into contact with the hypertrophied septum. This results in dynamic LVOT obstruction and coexisting posteriorly directed mitral regurgitation .
Physical Examination & Bedside Maneuvers
On auscultation, HOCM presents with a harsh crescendo-decrescendo systolic murmur at the left sternal border that does not radiate to the carotids (distinguishing it from aortic stenosis). Because LVOT obstruction is dynamic and dependent on LV cavity size, bedside maneuvers alter murmur intensity predictably:
Maneuver Change in Physiology Effect on LV End-Diastolic Volume Effect on LVOT Obstruction & Murmur Intensity
Valsalva Strain Phase Decreases venous return (preload) Decreases INCREASES (Smaller LV cavity = Leaflet closer to septum)
- Standing abruptly Decreases venous return (preload) Decreases INCREASES
- Nitrate Administration Decreases afterload and venous return Decreases INCREASES
Squatting Increases venous return and SVR (afterload) Increases DECREASES (Wider LV cavity separates leaflet from septum)
- Passive Leg Raise Increases venous return (preload) Increases DECREASES
- Handgrip exercise Increases SVR (afterload) Increases DECREASES
Exam Warning: Giving a patient with HOCM sublingual nitroglycerin or aggressive IV loop diuretics can induce catastrophic LVOT occlusion, sudden collapse, and cardiac arrest!
Diagnostic ECG Findings
Marked Left Ventricular Hypertrophy (Sokolow-Lyon criteria: S in V1 + R in V5/V6 > 35 mm).
Deep, narrow, dagger-like Q waves in lateral leads (I, aVL, V5, V6) representing early septal depolarization through hypertrophied tissue.
Pharmacological & Interventional Management
First-Line Pharmacotherapy: Non-vasodilating Beta-Blockers (metoprolol, atenolol, propranolol) titrated to a resting heart rate of 55–60 bpm. Beta-blockers prolong diastole (increasing LV filling/volume) and decrease contractility, relieving obstruction. Non-dihydropyridine Calcium Channel Blockers (Verapamil) are second-line.
Mavacamten (Camzyos): First-in-class selective cardiac myosin inhibitor . It targets the underlying pathophysiology by reducing functional myosin-actin cross-bridge formation, decreasing hypercontractility, and resolving LVOT gradients. Requires strict FDA REMS program monitoring of LVEF via baseline and serial echocardiograms (hold if LVEF < 50%).
Invasive Septal Reduction Therapy (SRT): Indicated for severe refractory symptoms with resting/provoked gradient ≥ 50 mmHg:
Surgical Septal Myectomy (Morrow Procedure): Gold standard resection of hypertrophied septal tissue.
Alcohol Septal Ablation (ASA): Injection of 1–2 mL of 98% dehydrated ethanol into the first major septal perforator artery via cardiac catheterization to induce a localized controlled septal infarction. High risk of complete heart block requiring permanent pacemaker.
Sudden Cardiac Death (SCD) Risk Stratification
Major risk factors warranting primary prevention ICD placement include:
History of unexplained sudden syncope.
Massive LV wall thickness ≥ 30 mm .
Family history of premature SCD in a first-degree relative.
Non-sustained ventricular tachycardia (NSVT) on ambulatory Holter monitoring.
LV apical aneurysm.
Restrictive Cardiomyopathy (RCM)
Restrictive Cardiomyopathy is the least common primary cardiomyopathy, characterized by rigid, non-compliant ventricular walls that severely impede diastolic filling while maintaining near-normal systolic function and ventricular dimensions (in early stages).
Etiologies & Classification
Infiltrative Diseases:
Cardiac Amyloidosis: Extracellular deposition of misfolded protein fibrils. Divided into AL Amyloidosis (immunoglobulin light chain, plasma cell dyscrasia) and ATTR Amyloidosis (Transthyretin type—wild-type/senile or hereditary mutations). Diagnosed via Pyrophosphate (PYP) bone scintigraphy or endomyocardial biopsy.
Sarcoidosis: Non-caseating granulomatous infiltration of the myocardium; frequently presents with high-grade AV block, ventricular tachycardia, and heart failure.
Storage Diseases: Hemochromatosis (iron overload), Fabry disease, glycogen storage disorders.
Non-Infiltrative / Fibrotic: Endomyocardial fibrosis, radiation-induced cardiomyopathy, scleroderma.
Diagnostic Hallmarks & Clinical Presentation
Echocardiography: Rigid ventricles with normal or small cavity sizes, concentric wall thickening, severe biatrial enlargement ("small ventricles with huge atria"), and prominent restrictive diastolic filling pattern (E/A ratio > 2.0, shortened deceleration time).
ECG Hallmark: Low-voltage QRS complexes across precordial and limb leads despite marked ventricular wall thickening on echocardiogram. This discordance between low ECG voltage and thick echo walls is pathognomonic for Cardiac Amyloidosis .
Physical Exam: Manifestations of predominant right-sided systemic congestion: severe peripheral edema, massive ascites, hepatomegaly, elevated JVP with prominent x and y descents, and Kussmaul's sign (paradoxical rise in JVP during inspiration).
Therapeutic Management
Disease-Specific Therapy: Tafamidis (Vyndaqel) binds transthyretin to prevent tetramer dissociation in ATTR Amyloidosis. Systemic corticosteroids/immunosuppressants for Sarcoidosis. Phlebotomy/iron chelation for Hemochromatosis.
Symptomatic Care: Careful diuresis to manage volume overload. Warning: Patients depend on elevated filling pressures to maintain stroke volume; excessive diuresis causes profound hypotension.
Takotsubo Cardiomyopathy (Stress-Induced / Broken Heart Syndrome)
Takotsubo Cardiomyopathy is a transient clinical syndrome characterized by acute regional left ventricular systolic dysfunction extending beyond a single epicardial vascular territory, triggered by severe emotional or physical stress. [Severe Emotional/Physical Stressor]
- ↓
- [Massive Endogenous Catecholamine Surge (Epinephrine/Norepinephrine)]
- ↓
- [Microvascular Spasm + Direct Cardiomyocyte Toxicity / Beta-2 Receptor Switch]
- ↓
- [Apical & Mid-Ventricular Akinesis + Basal Hyperkinesis ("Japanese Octopus Trap")]
- Clinical Presentation & Diagnostic Criteria (Mayo Clinic Criteria)
Presentation: Mimics acute STEMI—substernal chest pain, dyspnea, ischemic ECG changes (ST elevations in V2–V5, followed by deep T-wave inversions and QT prolongation), and mild troponin elevation disproportionate to the extensive wall motion abnormality.
Coronary Angiography: Crucial rule-out test demonstrating absence of obstructive coronary artery disease or acute plaque rupture.
Left Ventriculography: Classic appearance of apical ballooning (akinesis/dyskinesis of the apical and mid-ventricular segments with hyperkinesis of the basal walls).
Clinical Trajectory & Management
Prognosis: Excellent; complete resolution of LV systolic function typically occurs within 1 to 4 weeks .
Pharmacotherapy: Supportive care using ACE inhibitors/ARBs and beta-blockers until LVEF recovers completely. Exogenous sympathomimetics and inotropes (e.g., epinephrine) should be strictly avoided as they exacerbate catecholamine toxicity.
Complications: Acute heart failure/cardiogenic shock, dynamic LVOT obstruction (due to basal hyperkinesis), apical thrombus, and LV free wall rupture. In cardiogenic shock without LVOT obstruction, temporary mechanical circulatory support (IABP or Impella) is preferred over catecholamine inotropes.